285 related articles for article (PubMed ID: 24789589)
21. Pharmacological treatment of chronic heart failure.
Adorisio R; De Luca L; Rossi J; Gheorghiade M
Heart Fail Rev; 2006 Jun; 11(2):109-23. PubMed ID: 16937030
[TBL] [Abstract][Full Text] [Related]
22. Heart Failure Update: Outpatient Management.
Wojnowich K; Korabathina R
FP Essent; 2016 Mar; 442():18-25. PubMed ID: 26974001
[TBL] [Abstract][Full Text] [Related]
23. Heart Failure With Recovered Ejection Fraction in African Americans: Results From the African-American Heart Failure Trial.
Chang KW; Beri N; Nguyen NH; Arbit B; Fox S; Mojaver S; Clopton P; Tam SW; Taylor AL; Cohn JN; Maisel AS; Anand IS
J Card Fail; 2018 May; 24(5):303-309. PubMed ID: 28918108
[TBL] [Abstract][Full Text] [Related]
24. The isosorbide-hydralazine story: is there a case for race-based cardiovascular medicine?
Ferdinand KC
J Clin Hypertens (Greenwich); 2006 Mar; 8(3):156-8. PubMed ID: 16522991
[No Abstract] [Full Text] [Related]
25. The African American Heart Failure Trial: a clinical trial update.
Taylor AL
Am J Cardiol; 2005 Oct; 96(7B):44-8. PubMed ID: 16226935
[TBL] [Abstract][Full Text] [Related]
26. Novel heart failure drug may offer options for you.
Heart Advis; 2005 Sep; 8(9):2. PubMed ID: 16637097
[No Abstract] [Full Text] [Related]
27. [Programs for continuing medical education: B session; 1. The pathophysiology of heart failure--is it the disease of the heart?].
Kitakaze M
Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):681-6. PubMed ID: 24796136
[No Abstract] [Full Text] [Related]
28. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations.
Klein L; O'Connor CM; Gattis WA; Zampino M; de Luca L; Vitarelli A; Fedele F; Gheorghiade M
Am J Cardiol; 2003 May; 91(9A):18F-40F. PubMed ID: 12729848
[TBL] [Abstract][Full Text] [Related]
29. The treatment of chronic heart failure due to left ventricular systolic dysfunction.
Gardner RS; McDonagh TA
Clin Med (Lond); 2004; 4(1):18-22. PubMed ID: 14998261
[No Abstract] [Full Text] [Related]
30. Clinical treatment regimens for chronic heart failure: a review.
Gould PA; Kaye DM
Expert Opin Pharmacother; 2002 Nov; 3(11):1569-76. PubMed ID: 12437491
[TBL] [Abstract][Full Text] [Related]
31. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
Taylor AL; Ziesche S; Yancy CW; Carson P; Ferdinand K; Taylor M; Adams K; Olukotun AY; Ofili E; Tam SW; Sabolinski ML; Worcel M; Cohn JN;
Circulation; 2007 Apr; 115(13):1747-53. PubMed ID: 17372175
[TBL] [Abstract][Full Text] [Related]
32. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
Carson P; Ziesche S; Johnson G; Cohn JN
J Card Fail; 1999 Sep; 5(3):178-87. PubMed ID: 10496190
[TBL] [Abstract][Full Text] [Related]
33. Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.
Ferdinand KC; Elkayam U; Mancini D; Ofili E; Piña I; Anand I; Feldman AM; McNamara D; Leggett C
Am J Cardiol; 2014 Jul; 114(1):151-9. PubMed ID: 24846808
[TBL] [Abstract][Full Text] [Related]
34. G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT.
McNamara DM; Taylor AL; Tam SW; Worcel M; Yancy CW; Hanley-Yanez K; Cohn JN; Feldman AM
JACC Heart Fail; 2014 Dec; 2(6):551-7. PubMed ID: 25306451
[TBL] [Abstract][Full Text] [Related]
35. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
Taylor AL; Ziesche S; Yancy C; Carson P; D'Agostino R; Ferdinand K; Taylor M; Adams K; Sabolinski M; Worcel M; Cohn JN;
N Engl J Med; 2004 Nov; 351(20):2049-57. PubMed ID: 15533851
[TBL] [Abstract][Full Text] [Related]
36. Have we witnessed the rise and fall of race-specific drugs?
Coons SJ
Clin Ther; 2009 Mar; 31(3):620-2. PubMed ID: 19393852
[No Abstract] [Full Text] [Related]
37. The year in heart failure: 2004.
Massie BM
J Card Fail; 2005 Feb; 11(1):1-6. PubMed ID: 15704055
[No Abstract] [Full Text] [Related]
38. Race-based therapeutics.
Bloche MG
N Engl J Med; 2004 Nov; 351(20):2035-7. PubMed ID: 15533852
[No Abstract] [Full Text] [Related]
39. Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?
Ferdinand KC
J Law Med Ethics; 2008; 36(3):458-63. PubMed ID: 18840236
[TBL] [Abstract][Full Text] [Related]
40. The ABCs of managing systolic heart failure: Past, present, and future.
Okwuosa IS; Princewill O; Nwabueze C; Mathews L; Hsu S; Gilotra NA; Lewsey S; Blumenthal RS; Russell SD
Cleve Clin J Med; 2016 Oct; 83(10):753-765. PubMed ID: 27726827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
